Acquisition of Pelican Therapeutics (Schedule of Purchase Price of Assets and Liabilities) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Aggregate consideration:
Contingent consideration	$ 2,385,000
Purchase price allocation:
Goodwill	2,189,338
Pelican Therapeutics, Inc. [Member]
Aggregate consideration:
Cash consideration	500,000
Stock consideration	1,052,000
Contingent consideration	2,385,000
Total Consideration	3,937,000
Purchase price allocation:
Cash acquired	31,199
In-process R&D	5,866,000
Goodwill	2,189,338
Deferred tax liability	(2,111,760)
Net liabilities assumed	(1,102,777)
Fair value of non-controlling interest	(935,000)
Total purchase price	$ 3,937,000